Who are adalimumab, plus prednisone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adalimumab-plus-prednisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

adalimumab, plus prednisone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

adalimumab, plus prednisone (adalimumab, plus prednisone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (adalimumab) + corticosteroid (prednisone). Area: Immunology / Rheumatology.

marketed TNF-α inhibitor (adalimumab) + corticosteroid (prednisone) TNF-α receptor (adalimumab); glucocorticoid receptor (prednisone) Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

adalimumab, plus prednisone (adalimumab, plus prednisone) — Fondazione IRCCS Policlinico San Matteo di Pavia. Adalimumab blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation, while prednisone provides additional immunosuppression via glucocorticoid receptor activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
adalimumab, plus prednisone TARGET	adalimumab, plus prednisone	Fondazione IRCCS Policlinico San Matteo di Pavia	marketed	TNF-α inhibitor (adalimumab) + corticosteroid (prednisone)	TNF-α receptor (adalimumab); glucocorticoid receptor (prednisone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (adalimumab) + corticosteroid (prednisone) class)

Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). adalimumab, plus prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-plus-prednisone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab